Shares of Sangamo BioSciences, Inc. (NASDAQ:SGMO) have been assigned a consensus rating of “Hold” from the seven ratings firms that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $5.67.

A number of research firms recently commented on SGMO. Wedbush restated a “neutral” rating and issued a $4.00 price objective (down previously from $6.00) on shares of Sangamo BioSciences in a research report on Tuesday, May 16th. ValuEngine upgraded Sangamo BioSciences from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Zacks Investment Research upgraded Sangamo BioSciences from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. Cowen and Company reiterated a “buy” rating on shares of Sangamo BioSciences in a report on Tuesday, February 28th. Finally, Piper Jaffray Companies reiterated a “neutral” rating and set a $5.00 target price on shares of Sangamo BioSciences in a report on Tuesday, February 28th.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/06/19/sangamo-biosciences-inc-sgmo-receives-average-rating-of-hold-from-analysts.html.

Several institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. bought a new position in shares of Sangamo BioSciences during the fourth quarter valued at $179,000. Dimensional Fund Advisors LP boosted its position in shares of Sangamo BioSciences by 9.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 128,251 shares of the biopharmaceutical company’s stock valued at $391,000 after buying an additional 10,877 shares during the last quarter. Keybank National Association OH boosted its position in shares of Sangamo BioSciences by 43.3% in the fourth quarter. Keybank National Association OH now owns 135,247 shares of the biopharmaceutical company’s stock valued at $413,000 after buying an additional 40,854 shares during the last quarter. Royce & Associates LP boosted its position in shares of Sangamo BioSciences by 40.1% in the fourth quarter. Royce & Associates LP now owns 751,100 shares of the biopharmaceutical company’s stock valued at $2,291,000 after buying an additional 215,000 shares during the last quarter. Finally, A.R.T. Advisors LLC bought a new position in shares of Sangamo BioSciences during the fourth quarter valued at $161,000. Institutional investors own 59.23% of the company’s stock.

Shares of Sangamo BioSciences (NASDAQ SGMO) traded up 7.047% on Monday, hitting $7.975. The stock had a trading volume of 684,158 shares. The firm has a 50 day moving average price of $6.75 and a 200 day moving average price of $4.62. The company’s market capitalization is $573.71 million. Sangamo BioSciences has a one year low of $2.65 and a one year high of $8.60.

Sangamo BioSciences (NASDAQ:SGMO) last released its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.03. Sangamo BioSciences had a negative net margin of 380.44% and a negative return on equity of 50.76%. The business had revenue of $3.40 million during the quarter, compared to analysts’ expectations of $4.14 million. During the same quarter in the prior year, the company earned ($0.23) EPS. The firm’s quarterly revenue was down 12.8% on a year-over-year basis. On average, equities research analysts predict that Sangamo BioSciences will post ($0.94) earnings per share for the current fiscal year.

About Sangamo BioSciences

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Ratings for Sangamo BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.